FIGURE 1




FIGURE 2



Normal AAG
Unbound IC50
Elevated AAG (>1.1 g/L)
0.2 g/L AAG
4 g/L AAG
Predicted Unbound Concentration of ARRY-520 (ng/mL)
10
1
0.1
0.01
0
6
12
18
24
30
36
42
48
Time (hr)

FIGURE 3



Predicted Time (hr) Above Threshold (0.2 ng/mL Unbound ARRY-520)
144
120
96
72
48
24
0
0
0.6
1.2
1.8
2.4
3
3.6
4.2
[AAG] (g/L)

FIGURE 4



Ph1, ARRY-520 dose escalation (n = 27)
Ph2, ARRY-520 (n = 27)
Ph2, ARRY-520 + dex (n = 18)
[AAG] (g/L)
Unbound ARRY-520 (%)
2.8
2.4
2
1.6
1.2
0.8
0.4
1
1.5
2
2.5
3
3.5
4
4.5
5
5.5

FIGURE 5



Partial Response (n = 12)
Minimal Response (n = 4)
SD or PD (n = 56)
[AAG] (g/L)
2.8
2.4
2
1.6
1.2
0.8
0.4
5
10
15
20
25
30
35
Time on Treatment (months)

FIGURE 6



2.5
2.0
1.5
1.0
0.5
0.0
AAG (g/L)
Pool A
Pool B
Pool C
Pool D
Pool 1
Pool 2
Pool 3
Pool 4
Plasma
Serum

FIGURE 7



R&D Systems Quantikine vs. Siemens BNII
AAG (g/L)
Serum
y = 1.5146x - 0.0311
R square 0.7516
BNII
Quantikine
0.0
0.5
1.0
1.5
2.0
0
1
2
3

FIGURE 8



R&D Systems Quantikine vs. Siemens BNII
AAG (g/L)
Plasma
y = 1.3945x + 0.0426
R square
0.8824
BNII
Quantikine
0
1
2
3
0.0
0.5
1.0
1.5
2.0

FIGURE 9




R&D Systems Quantikine vs. Randox Imola
AAG (g/L)
Serum
y = 1.4427x - 0.0774
R square 0.7627
Imola
Quantikine
0
1
2
3
0.0
0.5
1.0
1.5
2.0

FIGURE 10


R&D Systems Quantikine vs. Randox Imola
AAG (g/L)
Plasma
y = 1.3615x - 0.0352
R square
0.8841
Imola
Quantikine
0
1
2
3
0.0
0.5
1.0
1.5
2.0